Mark Lawler: We call out for greater emphasis and investment in Lung Cancer Research

Mark Lawler shared a post by Lung Cancer Europe on X, adding:

“Lung cancer. 21% of cancer disease burden in Europe. But only 4% of the research effort and 4% of the research spend according to our The Lancet Oncology European Groundshot Commission. On World Lung Cancer Day we call out for greater emphasis and investment in Lung Cancer Research.”

Quoting Lung Cancer Europe’s post:

“Today is World Lung Cancer Day. Lung Cancer remains the leading cause of cancer-related deaths worldwide. Lung Cancer Europe and its members want governments in Europe and worldwide to work to improve the lives of people affected by lung cancer today and every day.”

Source: Mark Lawler/X and Lung Cancer Europe/X

Professor Mark Lawler holds the positions of Associate Pro-Vice-Chancellor, Professor of Digital Health, and Chair in Translational Cancer Genomics at the Faculty of Medicine, Health and Life Sciences at Queen’s University Belfast (QUB).

He serves on the Board of the European Alliance for Personalised Medicine (EAPM) and was instrumental in developing EAPM’s research strategy.

Additionally, he is a member of the Scientific Advisory Board of the European Cancer Patient Coalition and the Strategic Advisory Board of Genomics England.

His expertise includes genetics, precision medicine, health data, COVID-19, cancer, and patient and public involvement in research.